[BCRX] BioCryst Pharmaceuticals, Inc.


Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 6.99 Change: 0.59 (9.22%)
Ext. hours: Change: 0 (0%)

chart BCRX

Refresh chart

Strongest Trends Summary For BCRX

BCRX is in the long-term up 63% in 1 year.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule pharmaceuticals that block key enzymes involved in the pathogenesis of diseases. The company integrates the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to discover and develop drugs through the structure-guided drug design process. Its product candidates include peramivir, an intravenous neuraminidase inhibitor, which is approved for seasonal influenza in Japan and Korea, as well as to treat acute influenza; ulodesine, an oral purine nucleoside phosphorylase inhibitor, which has completed Phase II clinical trials for the treatment of gout; and forodesine, an oral purine nucleoside phosphorylase inhibitor that is in Phase II clinical trials for oncology. The company?s product candidates also comprise BCX4161, a Phase II oral serine protease inhibitor for hereditary angioedema (HAE); and BCX4430, a preclinical, RNA dependent-RNA polymerase inhibitor for treating Filovi

Fundamental Ratios
Shares Outstanding EPS-0.63 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 365.62% Sales Growth - Q/Q25.34% P/E-8.81
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-38.67% ROE-78.01% ROI
Current Ratio1.32 Quick Ratio Long Term Debt/Equity Debt Ratio0.96
Gross Margin Operating Margin-311.12% Net Profit Margin-295.81% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities1.5 M Cash From Investing Activities-3.95 M Cash From Operating Activities-3.73 M Gross Profit6.81 M
Net Profit-15.16 M Operating Profit-14.43 M Total Assets129.87 M Total Current Assets81.37 M
Total Current Liabilities61.86 M Total Debt30 M Total Liabilities65.5 M Total Revenue6.83 M
Technical Data
High 52 week9.72 Low 52 week4.6 Last close8.52 Last change-5.33%
RSI49.6 Average true range0.42 Beta1.24 Volume682.49 K
Simple moving average 20 days-4.23% Simple moving average 50 days-1.11% Simple moving average 200 days16.77%
Performance Data
Performance Week-5.33% Performance Month-3.29% Performance Quart-2.07% Performance Half16.55%
Performance Year77.5% Performance Year-to-date5.58% Volatility daily3.62% Volatility weekly8.09%
Volatility monthly16.58% Volatility yearly57.43% Relative Volume907.2% Average Volume734.14 K
New High New Low


2019-04-04 09:36:01 | Implied Volatility Surging for BioCryst Pharmaceuticals BCRX Stock Options

2019-04-01 07:00:00 | BioCryst to Present at Upcoming Investor Conferences

2019-03-25 14:10:07 | BioCryst Pharmaceuticals, Inc. NASDAQ:BCRX: What Can We Expect From This High Growth Stock?

2019-03-06 08:20:00 | Report: Developing Opportunities within Sarepta Therapeutics, Sally Beauty, Danaher, Ellie Mae, BioCryst Pharmaceuticals, and Akcea Therapeutics — Future Expectations, Projections Moving into 2019

2019-03-04 14:19:15 | Edited Transcript of BCRX earnings conference call or presentation 4-Mar-19 1:30pm GMT

2019-03-04 11:29:59 | Biocryst Pharmaceuticals Inc BCRX Q4 2018 Earnings Conference Call Transcript

2019-03-04 07:02:00 | BioCryst Reports Fourth Quarter and Full Year 2018 Financial Results

2019-03-04 07:00:00 | BioCryst Advancing BCX9930, an Oral Factor D Inhibitor for Complement-Mediated Diseases, into Phase 1 Development

2019-03-03 09:41:52 | The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs

2019-02-28 07:00:00 | BioCryst to Present at Barclays Global Healthcare Conference

2019-02-25 10:30:03 | Analysts Estimate BioCryst Pharmaceuticals BCRX to Report a Decline in Earnings: What to Look Out for

2019-02-23 12:45:00 | BioCryst Reports ZENITH-1 Results With Oral BCX7353 Which Confirm Rapid Onset of Action, Sustained Activity and Robust Dose Response for Treatment of Acute HAE Attacks

2019-02-18 07:00:00 | BioCryst to Report Fourth Quarter and Full Year 2018 Financial Results on March 4

2019-02-15 14:00:29 | The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings

2019-02-14 15:30:43 | Here Are 5 Biotech Stocks To Love This Valentine's Day: Analyst

2019-02-12 07:20:00 | Detailed Research: Economic Perspectives on Callon Petroleum, Summit Materials, Echo Global Logistics, BioCryst Pharmaceuticals, NEXEO SOLUTIONS, and NL Industries — What Drives Growth in Today's Competitive Landscape

2019-02-06 15:10:38 | How CEO Stonehouse is building up BioCryst's war chest to finance trials, drug launch

2019-02-06 07:00:00 | BioCryst Strengthens Cash Position With Flexible $100 Million Debt Facility

2019-02-05 07:00:00 | BioCryst to Present ZENITH-1 Results at American Academy of Allergy, Asthma & Immunology Annual Meeting

2019-01-04 07:00:00 | BioCryst Appoints Steve Aselage to Board of Directors

2019-01-02 07:00:00 | BioCryst Initiates Phase 1 Clinical Trial of Galidesivir

2019-01-02 07:00:00 | BioCryst to Present at 37th Annual J.P. Morgan Healthcare Conference

2018-12-27 09:23:36 | Stocks down in December for pharma firms in the Triangle

2018-12-16 09:13:13 | BioCryst Pharmaceuticals, Inc. BCRX Hedge Funds Are Snapping Up

2018-11-27 08:55:00 | New Research Coverage Highlights Immunomedics, Surmodics, PDF Solutions, Stepan, Express Scripts Holding, and BioCryst Pharmaceuticals — Consolidated Revenues, Company Growth, and Expectations for 2018

2018-11-20 07:00:00 | BioCryst Appoints Rare Disease Expert Theresa Heggie to Board of Directors

2018-11-16 07:00:00 | BioCryst Presents Data Highlighting the Rapid and Sustained Plasma Concentrations of BCX7353 in HAE Patients at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology

2018-11-08 07:00:00 | BioCryst to Present at Upcoming Investor Conferences

2018-11-07 07:35:26 | Edited Transcript of BCRX earnings conference call or presentation 6-Nov-18 1:30pm GMT

2018-11-06 08:30:01 | BioCryst Pharmaceuticals BCRX Reports Q3 Loss, Lags Revenue Estimates

2018-11-06 07:27:17 | BioCryst: 3Q Earnings Snapshot

2018-11-06 07:00:00 | BioCryst Reports Third Quarter 2018 Financial Results

2018-11-05 07:00:00 | BioCryst to Present Abstracts at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology

2018-10-30 10:33:02 | Earnings Preview: BioCryst Pharmaceuticals BCRX Q3 Earnings Expected to Decline

2018-10-23 16:15:00 | BioCryst to Report Third Quarter 2018 Financial Results on November 6

2018-10-16 07:50:00 | Analysis: Positioning to Benefit within Ardelyx, AXT, TG Therapeutics, MarineMax, Oclaro, and BioCryst Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results

2018-10-12 09:17:01 | Grifols GRFS Surges: Stock Moves 5.4% Higher

2018-09-25 16:15:00 | BioCryst Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference

2018-09-17 07:00:00 | BioCryst Receives Additional $3.5 Million to Fund Clinical Trials of Galidesivir in Yellow Fever

2018-09-13 14:03:50 | What Sarepta Therapeutics’ Valuation Trend Indicates

2018-09-10 12:36:00 | Here's Why BioCryst Pharmaceuticals Rose 21.3% in August

2018-09-06 13:45:00 | RTP pharma scores $35M contract to supply CDC

2018-09-06 07:37:00 | BioCryst stock surges 6% premarket after winning $35 million CDC contract for flu therapy

2018-09-06 07:00:00 | CDC Awards BioCryst $35 Million RAPIVAB® Contract for Strategic National Stockpile

2018-09-05 08:28:27 | The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results

2018-09-04 14:38:20 | Inside The List: Highest-Paid Public Company CEOs

2018-09-04 12:15:00 | CORRECTION -- BioCryst Reports Positive Results Across Multiple Endpoints in ZENITH-1 Trial of Oral BCX7353 as Acute Therapy for Hereditary Angioedema HAE Attacks

2018-09-04 07:00:00 | BioCryst Reports Positive Results Across Multiple Endpoints in ZENITH-1 Trial of Oral BCX7353 as Acute Therapy for Hereditary Angioedema HAE Attacks

2018-08-29 07:00:00 | BioCryst Pharmaceuticals to Present at the Baird Global Healthcare Conference

2018-08-17 21:40:44 | Edited Transcript of BCRX earnings conference call or presentation 7-Aug-18 3:00pm GMT